Are you concerned about your risk of Alzheimer's?
For the first time, there are treatments available that may help slow the progression of Alzheimer’s disease. The p-tau217 blood test helps you understand the likelihood of Alzheimer’s disease so your next steps are informed.
Life Line Screening p-tau217 Test – $499
Enter your details below and a preventative healthcare provider will call you to schedule your appointment. Screening options may include the p-tau217 blood test where available and clinically appropriate. Must be 55 or older.
For the first time, there are treatments available that may help slow the progression of Alzheimer’s disease. The p-tau217 blood test helps you understand the likelihood of Alzheimer’s disease so your next steps are informed.
Visit a Life Line Screening location to receive a simple blood test. No fasting required.
A specialized lab analyzes your blood sample for p-tau217.
Test results delivered to you within 15 business days to share and discuss with your doctor about next steps if needed.
Service Availability
The p-tau217 test is performed at convenient Life Line Screening locations near you, including community centers, hotels, and local venues in your area. Our Concierge team will help you schedule your screening once requested.
Identify biomarker changes, years before symptoms appear, helping you guide evaluation, monitoring, and lifestyle strategies with your primary care provider.
Memory concerns can be stressful. Biomarker-informed discussions can bring structure to next steps—rather than guessing.
A p-tau217 blood test provides useful information for you and your healthcare provider to help determine whether you need more evaluation, monitoring, or lifestyle changes. Trust the preventative health partner who brings screening directly into your community.
11M+
Customers Screened
15k+
Locations
30+
Years Experience
No, fasting is not necessary.
The screening requires a standard venous blood draw, similar to what a doctor orders during routine lab work. Only one tube is collected—about a teaspoon of blood.
No. This is a not a clinical research study.
Yes. If the customer chooses to add the Alzheimer’s Risk Biomarker Screening, the fee is $499.
No. Health insurance does not typically cover this screening, and it is not billed through insurance.
This screening will be done during your screening visit.
Results can be found in the LLS results portal. In addition, if your results show elevated levels of p-tau217 a copy will be mailed directly to you.
This test may help determine the likelihood of developing Alzheimer’s disease within the next 10–20 years. It does not confirm whether a person will or will not develop Alzheimer’s disease. It provides an indication of risk based on detection of the p-tau217 biomarker.
Very few companies offer this blood test, and most require cognitive testing or existing symptoms before screening. Life Line Screening is one of the only organizations offering it without those requirements, allowing us to offer a complex test at a reasonable price.
Additionally, the lab analysis required for this test uses specialized technology that is more complex than typical bloodwork.
No. Dementia is a general term for symptoms such as memory loss, confusion, or behavioral changes. These symptoms can have many causes, such as Parkinson’s disease or Lewy Body disease.
Alzheimer’s disease is one specific cause of dementia and can be associated with abnormal amyloid and tau proteins in the brain.
A high result indicates that p-tau217 was detected at levels that may suggest ongoing changes or future changes in the brain. It does not confirm that the individual has Alzheimer’s disease.
There is no proven way to prevent Alzheimer’s disease. However, advancements in the field of brain health and prescribed medications have made major improvements in slowing the progression of the disease.
In addition, lifestyle habits—such as learning new skills, exercising, reading, maintaining healthy blood pressure, and following a healthy diet—may delay or reduce the severity of symptoms.
There are newly approved medications that can reduce the buildup of certain proteins in the brain and may significantly slow disease progression. Other medications can help manage symptoms. Advancements in medicine continue to occur so having this information can be helpful as further treatment options become available.
This is a preventative screening offering and not a diagnostic tool. It would not be appropriate for someone that has already been diagnosed.
At present, there are no established clinical guidelines that specify how often p-tau217 testing should be repeated. P-tau217 is not a standalone diagnostic test and should be interpreted within the context of the patient's clinical picture. Repeat testing decisions should also be made with clinical discretion including possibly when additional evaluation is warranted, symptoms progress, or more information becomes available.
Still have questions? Our concierge team is here to help.
Call (833) 517-0006